Abstract library

18 results for "Otero-Anton".
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis
#75 Carcinoid and carcinoid syndrome: analysis of 110 cases from a single insitute
Introduction: Carcinoid syndrome (CS) often presents with flushing, diarrhea and carcinoid heart disease (CHD).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Emilio Bajetta
#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#838 Succinate Dehydrogenase Subunit B (SDHB) Immunohistochemistry Should Not Replace Clinical Genetic Testing for SDHx Mutations in Patients with Pheochromocytoma and Paraganglioma
Introduction: Mutations in any of the subunits of the succinate dehydrogenase (SDH) complex predispose to PCC/PGL. Knowing the germline mutation is important for surveillance for recurrence, metastatic disease or more primary tumors and for screening affected family members. Expression of SDHB protein by immunohistochemistry (IHC) has been proposed as a surrogate marker for SDHx mutation status, with absent or decreased expression of SDHB suggesting the presence of a germline SDHB mutation or disruption of the SDH complex by mutation in another subunit.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Lauren Fishbein
#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy
Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Suzanne Richter
Keywords: PRRT
#1448 Distribution of T-Cell Infiltrate in G1, G2 and G3 NENs
Introduction: The identification of T-cell infiltrate and the expression of inhibitory molecules in the tumor microenvironment could lend support to the use of immunotherapy in the treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: Ki-67, T-cells, NEN
#1451 Pancreatic NENs <2 cm Could Represent a New Entity Worth of Further Investigation
Introduction: Surgical approach to the treatment of well-differentiated pancreatic neuroendocrine neoplasms (pNENs) is based on tumor size and Ki67. Surgical removal is not recommended for tumors <2cm, due to their indolent nature. Ki67≤2% and size <2cm are considered indicative of benign tumors. However, size and Ki67 may not correctly predict the prognosis of patients with pNENs <2cm.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: NEN, <2cm, prognosis
#1753 Ki67 Is Able to Predict Pancreatic NENs Prognosis Irrespective of Their Size
Introduction: In pancreatic neuroendocrine neoplasms (pNENs), size <20mm and Ki67≤2% suggest indolent behavior. None of these factors alone predicts prognosis. No other predictive factors have been suggested.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: MD, PhD Massimo Milione
Keywords: Ki67, PFS, pancreatic, NEN
#1755 Immune-Related Factors Analysis Enhances the Stratification of GEP-NENs Patients Into Distinct Prognostic Subsets
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are divided into different prognostic categories according to Ki67 class (≤2%: 2%-20%; 20%-55%; >55%); treatment strategies based on this classification are not fully effective.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione